New Dosing Regimen for Lexiva Approved
October 12, 2007
On October 12, 2007, the Food and Drug Administration (FDA) approved a supplemental new drug application for Lexiva (fosamprenavir calcium; FPV) Oral Tablets, adding a new indication for once-daily dosing of 1400 mg of Lexiva with 100 mg ritonavir for the treatment of HIV infection in therapy-naive adults. The approval was based on a bioavailability study demonstrating that this dosing regimen produced drug levels bracketed within those of the already approved 1400 mg once daily plus ritonavir 200 mg once daily regimen, and the Lexiva 1400 mg twice daily dosing regimen.
Lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, and is distributed by GlaxoSmithKline, Research Triangle Park, NC.
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.